CERT Certara

Certara Automates Scientific Workflows with Phoenix® Cloud

Certara Automates Scientific Workflows with Phoenix® Cloud

New cloud capabilities cut time to create Tables, Figures, and Listings by 50%

RADNOR, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of TFL Studio, the first cloud-native module of its Phoenix Cloud solution. TFLs (Tables, Figures, and Listings) present data on study participants, treatments, and outcomes visually for clear interpretation. They are critical components of regulatory submissions and scientific publications. TFL Studio lets pharmacokinetic (PK) and pharmacodynamic (PD) scientists create these components with greater speed and collaboration.

Traditional TFL workflows are often hindered by manual processes, fragmented tools, and the challenges of maintaining visual quality and consistency across studies. Phoenix Cloud is designed to accelerate these and related PK workflows through AI and cloud technology.

"The introduction of TFL Studio marks a pivotal moment in our mission to bring advanced, cloud-native solutions to drug discovery and development," said William F. Feehery, Chief Executive Officer.



A complementary module, AI PK Reports, will be released this quarter. AI PK Reports leverages GenAI to turn tables, figures, and listings into draft PK reports, reducing a process that typically takes scientists days to complete down to minutes. AI PK Reports are powered by , Certara’s GenAI software for regulatory and medical writing.

TFL Studio delivers a user-friendly, no-code environment where scientists can:

  • Build TFLs Faster with Reusable Templates: Create, maintain, and apply standardized templates, reducing setup time and ensuring consistency.

  • Generate Dynamic, Editable Outputs: Easily fine-tune TFLs from source data without intermediate preparation, streamlining the editing and review process.

  • Lower Training Burden: Intuitive tools and transparent workflows make it easier for new users to quickly become proficient, fostering broader adoption across teams.

"TFL Studio empowers scientists to create high-quality TFLs up to 50% faster, freeing them from the technical complexities of moving source data, coding, and manual formatting,” said Martin Snyder, President, Certara Data Sciences. “This allows them to focus on science, derive insights more quickly, and ultimately accelerate critical decision-making."

As the inaugural cloud-native module of Phoenix Cloud, TFL Studio sets the stage for future innovations, including the AI PK Reports module described above. It integrates with , providing a single source of truth for PK/PD data, models and visualizations.

TFL Studio is available now as part of the Phoenix Cloud solution. To learn more about TFL Studio and the Phoenix Cloud platform, visit .

About Certara

Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Learn more at

Certara contact:

Sheila Rocchio

Media contact:

Alyssa Horowitz



EN
04/11/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Certara

 PRESS RELEASE

Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic...

Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib Biosimulation results highlight how model-informed approaches for drug development and regulatory decision-making save time and money.  RADNOR, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its enabled physiologically-based pharmacokinetic (PBPK) modeling predictions accepted by the U.S. FDA in lieu of clinical studies to support the new drug application (NDA) for asciminib (Scemblix®)...

 PRESS RELEASE

Certara to Participate in Upcoming Investor Conferences

Certara to Participate in Upcoming Investor Conferences RADNOR, Pa., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference Date and Time: Tuesday, March 3rd, 2026, at 3:10PM ET Leerink Global Healthcare Conference Date and Time: Monday, March 9th, 2026, at 8:00AM ET Barclays 28th Annual Global Healthcare ConferenceDate and Time: Tuesday, March 10th, 2026, at 1:00PM ET Live webcasts for ...

 PRESS RELEASE

Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Y...

Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Guidance FY 2025 Revenue of $418.8M (9% growth) and Adj. EBITDA of $134.5M (10% growth) Fourth Quarter Revenue of $103.6M (3% growth) and Adj. EBITDA of $32.5M (-3% decline) FY 2026 Revenue Growth of 0-4% FY 2026 Adjusted EBITDA Margin of 30-32% FY 2026 Adjusted Diluted EPS of $0.44-$0.48 RADNOR, Pa., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its fourth quarter and full fiscal year 2025 financial results. Fourth Quart...

 PRESS RELEASE

Certara to Report Fourth Quarter and Full Year 2025 Financial Results ...

Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2025 RADNOR, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2025 before market open on Thursday, February 26th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET. Investors interested in listening to the conference call are required to . It is recommended to register at least one day in adva...

 PRESS RELEASE

Certara Reports Third Quarter 2025 Financial Results

Certara Reports Third Quarter 2025 Financial Results  Updates Full Year 2025 Financial Guidance RADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2025. Third Quarter Highlights: Revenue was $104.6 million, compared to $94.8 million in the third quarter of 2024, representing growth of 10%. Software revenue was $43.8 million, compared to $35.9 million in the third quarter of 2024, representing growth of 22%.Services revenue was $60.8 m...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch